Protalix BioTherapeutics, Inc. (AMEX: PLX) is a Healthcare company (Biotechnology) with a market capitalization of $243M. The Maz Rating grades it against the other companies in its sector.
Protalix BioTherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.88, Protalix BioTherapeutics, Inc. trades at 11.0x trailing earnings, 2.9x sales and 2.9x book value, with an EV/EBITDA of 8.1. Over the last twelve months it generated about $85M of revenue and $22M of net income. It runs a gross margin of 71.2%, an operating margin of 29.8% and a net margin of 24.3%. It shows return on equity of 30.7%, return on invested capital of 22.3% and a free cash flow yield of 6.2%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 3.27. Over the past 52 weeks the share price ranged from $1.65 to $3.19, with a beta of 0.01.
Protalix BioTherapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Protalix BioTherapeutics, Inc. (PLX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.9% / 30% · Interest income / Revenue 2.73% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.9% / 33% · Receivables / Mkt Cap (36m) 6.56% / 49% · Interest income / Revenue 2.73% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.9% / 33.33% · Receivables / Mkt Cap (24m) 6.56% / 33.33% · Interest income / Revenue 2.73% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.35% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 41.4% / 33.33% · Receivables / Avg Assets (4Q) 10.2% / 33.33% · Interest income / Revenue 2.73% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 41.0% / 33.33% · (Cash+Recv) / Total Assets 52.8% / 33.33% · Interest income / Revenue 2.73% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Protalix BioTherapeutics, Inc. (PLX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Protalix BioTherapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.73% of each dividend: Protalix BioTherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.